Generic entry timeline

COCAINE HYDROCHLORIDE generics — when can they launch?

COCAINE HYDROCHLORIDE (COCAINE HYDROCHLORIDE) · · 23 active US patents · 0 expired

Earliest patent expiry
2037-02-07
11 years remaining
Full patent estate to
2037-02-07
complete protection through 2037
FDA approval
2017

Where COCAINE HYDROCHLORIDE sits in the generic timeline

Long-dated protection: earliest active US patent for COCAINE HYDROCHLORIDE extends to 2037 (~11 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Method of Use — 19 patents
  • Formulation — 4 patents

FDA U-codes carved out by COCAINE HYDROCHLORIDE patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-2478(no description)
U-2225(no description)
U-3014(no description)
U-3680(no description)
U-2226(no description)
U-2329(no description)
U-2479(no description)

Sample patent estate

Showing 6 of 23 active US patents. View full estate on the COCAINE HYDROCHLORIDE drug page →

  • US10933060 Method of Use · expires 2037-02-07
    This patent protects novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those compositions.
    USPTO title: Pharmaceutical compositions and methods of using the same
  • US11040032 Formulation · expires 2037-02-07
    This patent protects novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those compositions.
    USPTO title: Pharmaceutical compositions and methods of using the same
  • US11040032 Formulation · expires 2037-02-07
    This patent protects novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those compositions.
    USPTO title: Pharmaceutical compositions and methods of using the same
  • US10987347 Method of Use · expires 2037-02-07
    This patent protects novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those compositions.
    USPTO title: Pharmaceutical compositions and methods of using the same
  • US10149843 Method of Use · expires 2037-02-07
    This patent protects novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those compositions.
    USPTO title: Pharmaceutical compositions and methods of using the same
  • US10894012 Method of Use · expires 2037-02-07
    This patent protects novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those compositions.
    USPTO title: Pharmaceutical compositions and methods of using the same

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on COCAINE HYDROCHLORIDE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →